Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hyperlipoproteinemias

  Free Subscription


Articles published in JAMA

Retrieve available abstracts of 25 articles:
HTML format
Text format



Single Articles


    August 2017
  1. FERENCE BA, Kastelein JJP, Ginsberg HN, Chapman MJ, et al
    Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
    JAMA. 2017 Aug 28. doi: 10.1001/jama.2017.11467.
    PubMed     Text format     Abstract available


  2. KAZI DS, Penko J, Coxson PG, Moran AE, et al
    Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
    JAMA. 2017;318:748-750.
    PubMed     Text format    


  3. KRUMHOLZ HM
    Treatment of Cholesterol in 2017.
    JAMA. 2017;318:417-418.
    PubMed     Text format    


    July 2017
  4. KNOWLES JW, Rader DJ, Khoury MJ
    Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing.
    JAMA. 2017;318:381-382.
    PubMed     Text format    


  5. IOANNIDIS JPA
    Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
    JAMA. 2017 Jul 24. doi: 10.1001/jama.2017.6765.
    PubMed     Text format    


    April 2017
  6. SCHWARTZ MLB, Williams MS, Murray MF
    Adding Protective Genetic Variants to Clinical Reporting of Genomic Screening Results: Restoring Balance.
    JAMA. 2017;317:1527-1528.
    PubMed     Text format    


  7. GOTTESMAN RF, Schneider AL, Zhou Y, Coresh J, et al
    Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition.
    JAMA. 2017;317:1443-1450.
    PubMed     Text format     Abstract available


    August 2016
  8. KAZI DS, Moran AE, Coxson PG, Penko J, et al
    Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    JAMA. 2016;316:743-53.
    PubMed     Text format     Abstract available


  9. LOZANO P, Henrikson NB, Dunn J, Morrison CC, et al
    Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:645-55.
    PubMed     Text format     Abstract available


  10. BIBBINS-DOMINGO K, Grossman DC, Curry SJ, Davidson KW, et al
    Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2016;316:625-33.
    PubMed     Text format     Abstract available


  11. URBINA EM, de Ferranti SD
    Lipid Screening in Children and Adolescents.
    JAMA. 2016;316:589-91.
    PubMed     Text format    


    April 2016
  12. NISSEN SE, Stroes E, Dent-Acosta RE, Rosenson RS, et al
    Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    JAMA. 2016;315:1580-90.
    PubMed     Text format     Abstract available


  13. WATERS DD, Hsue PY, Bangalore S
    PCSK9 Inhibitors for Statin Intolerance?
    JAMA. 2016;315:1571-2.
    PubMed     Text format    


    March 2016
  14. SHRANK WH, Barlow J
    New Strategies to Treat High Cholesterol--Reply.
    JAMA. 2016;315:1169-70.
    PubMed     Text format    


  15. BLUM CB, Stone NJ
    New Strategies to Treat High Cholesterol.
    JAMA. 2016;315:1169.
    PubMed     Text format    


    December 2015
  16. JIN J
    JAMA PATIENT PAGE. PCSK9 Inhibitors for Treating High Cholesterol.
    JAMA. 2015;314:2320.
    PubMed     Text format    


    November 2015
  17. PURSNANI A, Massaro JM, Hoffmann U
    Predicted vs Observed Clinical Event Risk for Cardiovascular Disease-Reply.
    JAMA. 2015;314:2082-2083.
    PubMed     Text format    


  18. DEFILIPPIS AP, Blaha MJ
    Predicted vs Observed Clinical Event Risk for Cardiovascular Disease.
    JAMA. 2015;314:2082.
    PubMed     Text format    


    October 2015
  19. SHRANK WH, Barlow JF, Brennan TA
    New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines.
    JAMA. 2015;314:1443-4.
    PubMed     Text format    


  20. GANDA OP
    Failure to Report Financial Disclosure Information.
    JAMA. 2015;314:1404.
    PubMed     Text format    


    July 2015
  21. MITKA M
    Exploring Statins to Decrease HIV-Related Heart Disease Risk.
    JAMA. 2015 Jul 29. doi: 10.1001/jama.2015.5498.
    PubMed     Text format    


  22. PURSNANI A, Massaro JM, D'Agostino RB Sr, O'Donnell CJ, et al
    Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.
    JAMA. 2015;314:134-41.
    PubMed     Text format     Abstract available


  23. GREENLAND P, Lauer MS
    Cholesterol Lowering in 2015: Still Answering Questions About How and in Whom.
    JAMA. 2015;314:127-8.
    PubMed     Text format    


    June 2015
  24. GANDA OP
    Clinician Understanding of Cholesterol Treatment Guidelines--Reply.
    JAMA. 2015;313:2382.
    PubMed     Text format    


  25. LEE TC, McDonald EG
    Clinician Understanding of Cholesterol Treatment Guidelines.
    JAMA. 2015;313:2381-2.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: